alpha-glucosidase inhibitor

(redirected from Alpha glucosidase inhibitor)

α-glucosidase inhibitor

an oral agent that aids in the control of diabetes mellitus by delaying the absorption of glucose from the digestive system.

alpha-glucosidase inhibitor

any of a group of oral antihyperglycemic agents that act by competitive inhibition of alpha-glucosidase, delaying intestinal carbohydrate absorption and lessening postprandial increases in glucose levels.

alpha-glucosidase inhibitor

An oral drug that lowers blood sugars by preventing carbohydrate absorption from the gastrointestinal tract.

α-glu·co·si·dase in·hib·i·tor

(glū-kō'si-dās in-hib'i-tŏr)

Oral agent that aids control of diabetes mellitus by delaying absorption of glucose from digestive system.

Mentioned in ?

References in periodicals archive ?

In a further study, linagliptin monotherapy showed superiority in glucose lowering versus placebo and versus voglibose, the most commonly used alpha glucosidase inhibitor in Japan.

Linagliptin 'significantly lowers blood glucose'

Antidiabetic medicinal plants as a source of alpha glucosidase inhibitors.

In vitro inhibitory potential of Cynara scolymus, Silybum marianum, Taraxacum officinale, and Peumus boldus on key enzymes relevant to metabolic syndrome

The prescribed alpha glucosidase inhibitors were- voglibose 0.

However pioglitazone combination therapy with metformin and alpha glucosidase inhibitors (regimen C and D) revealed lower weight and BMI gain: 0.

Pioglitazone induced weight changes in type 2 diabetic patients

Metformin, Sulfonylureas, thaizolidinediones, dipeptidyl inhibitors, meglitinides, alpha glucosidase inhibitors, combination medications)

TABLE 15 BRIC ALPHA GLUCOSIDASE INHIBITORS MARKET, BY GEOGRAPHY 2007 - 2014 ($MILLIONS)

Reportlinker Adds BRIC Diabetes Drugs Market

Injectables Market: (Insulin, exenatide) - Oral Drugs Market: (Metformin, sulfonylureas, thaizolidinediones, dipeptidyl inhibitors, meglitinides, alpha glucosidase inhibitors, combination medications)

MarketsandMarkets: BRIC Diabetes Drugs Market Worth US$8.7 Billion By 2014

medications include alpha glucosidase inhibitors such as Precose

AMERICAN DIABETES ASSOCIATION ENCOURAGES MANAGED CARE ORGANIZATIONS TO ADOPT PREVENTION STRATEGIES FOR DIABETES